New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
09:23 EDTGRFS, ING, EXAS, HALO, AMGN, PRAN, CRIS, SINA, MNKD, LULUOn The Fly: Pre-market Movers
HIGHER: Lululemon (LULU), up 3% following upgrade at Wedbush... SINA (SINA), up 3.5% after upgraded at Pacific Crest... Grifols (GRFS), up 2.5% after announcing 7-year agreement with Japanese Red Cross... Exact Sciences (EXAS), up 3.6% after Barron's says shares could rise 50%... Curis (CRIS), up 11% after announcing removal of FDA partial clinical hold on CUDC-427... Halozyme (HALO), up 9% after announcing that trial of Hylenex recombinant met primary endpoint... ING (ING), up 4.5% after paying EUR1.23B to Dutch State... Amgen (AMGN), up 2% after AMG 145 reduced LDL cholesterol in statin intolerant patients... LOWER: Prana (PRAN), down 66% after Alzheimer's study doesn't hit targets... MannKind (MNKD), down 5.6% after downgraded at Piper Jaffray.
News For LULU;MNKD;PRAN;EXAS;SINA;AMGN;ING;CRIS;HALO;GRFS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 13, 2014
06:04 EDTLULUStocks with implied volatility above IV index mean; GME LULU
Subscribe for More Information
November 12, 2014
16:46 EDTINGVoya Financial announces offering of 34.5M shares of common stock by ING Group
Subscribe for More Information
14:53 EDTSINASINA weekly volatility elevated into Q3 and outlook
SINA November weekly call option implied volatility is at 107, December is at 41, January is at 39; compared to its 26-week average of 46 according to Track Data, suggesting large near term price movement into the expected release of Q3 results on November 13.
13:31 EDTLULULululemon Athletica volatility elevated as shares trend higher
Subscribe for More Information
05:50 EDTMNKDStocks with implied volatility movement; MNKD XLF
Stocks with implied volatility movement; MannKind (MNKD) 65, Financial Select Sector (XLF) 15 according to iVolatility.
November 11, 2014
16:05 EDTAMGNAmgen, AstraZeneca say Phase 3 brodalumab study met endpoints
Subscribe for More Information
16:01 EDTMNKDOptions Update; November 11, 2014
Subscribe for More Information
10:44 EDTAMGNAmgen reaffirms 2015 adjusted EPS outlook $9.05-$9.40
Subscribe for More Information
09:18 EDTHALOHalozyme price target lowered to $10 from $12 at JMP Securities
JMP Securities cut its price target on Halozyme after the company said it intends to explore partnerships and/or strategic alternatives for the Hylenex program in diabetes. The firm removed the diabetes program from its valuation due to uncertainty. It reiterates an Outperform rating on the shares.
November 10, 2014
18:32 EDTHALOOn The Fly: After Hours Movers
Subscribe for More Information
17:26 EDTHALOHalozyme completes workforce reduction
The company noted, "We completed a corporate reorganization to align with strategic priorities. This reorganization resulted in a workforce reduction of 22 employees. We will incur a one-time charge in Q414 that will be largely offset by reduced compensation expenses during the quarter."
16:19 EDTHALOHalozyme reports Q3 EPS (16c), consensus (14c)
Subscribe for More Information
15:54 EDTAMGNAmerican Society of Nephrology to hold a conference
Subscribe for More Information
15:26 EDTHALONotable companies reporting after market close
Subscribe for More Information
09:46 EDTLULUBB&T remains positive on lululemon following channel checks
BB&T said it remains positive on lululemon following recent channel checks. The firm continues to expect lululemon's results to improve as the company improved product assortment and laps 2013 PR stumbles. BB&T views the hire of Duke Stump as EVP of Community and Brand as a a positive and views the controversy over the donation to the Dalai Lama Center as overblown. Shares are Buy rated with a $50 price target.
07:22 EDTLULUU.S. Retail Softlines sector downgraded to Negative at Barclays
Subscribe for More Information
07:18 EDTCRISCuris provides pipeline update for CUDC-907, CUDC-427, Debio 0932
A total of 41 patients with relapsed/refractory lymphomas or multiple myeloma have been enrolled thus far, with 10 patients continuing to receive treatment in the dose escalation and expansion phases of the single agent, first-in-human Phase 1 clinical study of CUDC-907. The safety profile of CUDC-907 has been consistent with prior reports of diarrhea and thrombocytopenia as the most frequent adverse events, with diarrhea and hyperglycemia identified as dose limiting toxicities. Curis has completed enrollment in all consecutive, escalating dose cohorts at 100, 200 or 300 mg per day in the single-agent Phase 1 study of CUDC-427 in patients with advanced and/or refractory solid tumors or lymphoma. The primary objective of this monotherapy study under the amended protocol is to determine the safety and recommended Phase 2 dose for CUDC-427 when administered orally once daily for two weeks, followed by a one week rest period in 21-day cycles until disease progression or study discontinuation. Curis collaborator Debiopharm has decided that the Phase 1 dose escalation data from the Phase 1/2 HALO study of Debio 0932 in combination with 3 different standard-of-care chemotherapy regimens in an unselected population of patients with advanced or metastatic non-small cell lung cancer were inconclusive, and has opted not to advance Debio 0932 into the Phase 2 portion of the study. No new Debio 0932-related side effects were identified and safety observations were generally consistent with the expected side effects of Debio 0932 and/or the respective chemotherapeutic regimens administered in the study. Curis expects to receive formal notice of termination of the license agreement from Debiopharm shortly and the partners are expected to enter into a transition agreement in the fourth quarter of 2014 regarding the orderly return of the program and all rights to Curis.
07:17 EDTCRISCuris reports Q3 EPS (6c), consensus (4c)
Reports Q3 revenue $1.78M, consensus $4.13M
06:46 EDTINGRegulators set new capital buffer rule for banks, Reuters reports
Global banks should have buffers of bonds or equity worth 16%-20% of their risk-weighted assets, beginning in January 2019, The Financial Stability Board decided, according to Reuters. The board said the buffer would prevent the need for government bailouts, the news service explained. Publicly traded global banks include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) Wells Fargo (WFC), Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), RBS (RBS) and UBS (UBS). Reference Link
05:48 EDTLULUU.S. Retail Softlines industry cut to Negative at Barclays
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use